A critical review of the management of bladder cancer

Critical Reviews in Oncology/Hematology

Volumn 31, Issue 3, 1999, Pages 193-207

  Sternberg, Cora N ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; ANTIINFECTIVE AGENT; AROMATIC AMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DYE; EPIRUBICIN; ETOGLUCID; ETRETINATE; FLUOROURACIL; GADOLINIUM; GRANULOCYTE COLONY STIMULATING FACTOR; HAIR DYE; IFOSFAMIDE; MITOMYCIN C; PACLITAXEL; PHENACETIN; THIOTEPA;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; NUCLEAR MAGNETIC RESONANCE; PROGNOSIS; RECURRENT DISEASE; REVIEW; TRANSITIONAL CELL CARCINOMA;

ANIMALS; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 0032880288     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00031-1     Document Type: Review

References (127)

1. American Cancer Society. What are the key statistics about bladder cancer?, Internet Communication 1998.
2. Fact sheet: twelve major cancers, Sci Am 1996;275(3):92-98.
3. Shirai T., Fradet Y., Huland H. The etiology of bladder cancer: are there any new clues of predictors of behavior? Int J Urol. 2(Suppl 2):1995;64-75.
4. Jones P.A., Droller M.J. Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. Semin Urol. 11(4):1993;177-192.
5. Sandberg A.A., Berger C.S. Review of chromosome studies in urological tumors II. Cytogenetics and molecular genetics of bladder cancer. J Urol. 151:1994;545-560.
6. Knowles M.A., Elder P.A., Williamson M. et al. Allelotype of human bladder cancer. Cancer Res. 54:1994;531-537.
7. Reznikoff C.A., Belair C.D., Yeager T.R. A molecular genetic model of human bladder cancer pathogenesis. Sem Oncol. 23(5):1996;571-584.
8. Esrig D., Spruck III C.H., Nichols P.W. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Path. 143:1993;1389-1397.
9. Spruck III C.H., Ohneseit P.E., Gonzalez-Zulueta M. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54:1994;784-788.
10. Schultz P.K., Herr H.W., Zhang Z. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients with M-VAC with 5 years follow-up. J Clin Oncol. 12(7):1994;1394-1401.
11. Burchill S.A., Neal D., Lunec J. Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br J Urol. 73:1994;516-521.
12. Wright C., Mellon K., Johnston P. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer. 63:1991;967-970.
13. Imai T., Kimura M., Takeda M. Significance of epidermal growth factor receptor and -ERB-2 protein expression in transitional cell cancer of the upper urinary tract for tumor recurrence at the urinary bladder. Br J Cancer. 71:1995;69-72.
14. Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer. 29A (suppl):1993;749-753.
15. Underwood M., Bartlett J., Reeves J. c-erb-2 gene amplification a molecular marker in recurrent bladder tumors. Cancer Res. 55:1995;2422-2430.
16. Sternberg C.N., Swanson D.A. Non transitional cell bladder cancer. Raghavan D., Scher H.I., Leibel S.A. et al. Principles and Practice of Genitourinary Oncology. 1997;315-330 Philadelphia, Lippincott-Raven.
17. Sternberg C.N. Cancers of the genito-urinary tract. Cavalli F., Hansen H., Kaye S.B. Textbook of Medical Oncology. 1997;183-216 Martin Dunitz Ltd, London.
18. Sternberg C.N. The treatment of advanced bladder cancer. Ann Oncol. 6(2):1995;113-126.
19. Sarosdy M.F., Hudson M.A., Ellis W.J. et al. Improved detection of recurrent bladder cancer using the Bard BTA Test. Urology. 50(3):1997;349-353.
20. Ianari A., Sternberg C., Pansadoro V. Results of BARD test in monitoring patients with a history of transitional cell carcinoma of the bladder. Urology. 49(5):1997;786-790.
21. Bade S., Kahla-Witsch H., Schuldes H. et al. Uroplakin RT-PCR: specific and sensitive detection of bladder carcinoma cells. Br J Urol. 80(Suppl 2):1997;24. (Abstract 90).
22. Muzzonigro G., Minardi D., Galosi A.B. et al. Urinary NMP22 as a new marker in patients with transitional cell carcinoma: preliminary report. Br J Urol. 80(Suppl 2):1997;61. (Abstract 238).
23. Linn J.F., Wang Y., Steiner G. et al. Microsatellite based detection of bladder cancer by analysis of urine using fast capillary array elctrophoresis and fluorescent primers. Br J Urol. 80(Suppl 2):1997;23. (Abstract 85).
24. Sidransky D. Advances in cancer detection. Sci. Am. 275(3):1996;70-75.
25. Heney N.M., Ahmed S., Flanagan M.J. Superficial bladder cancer: progression and recurrence. J Urol. 130:1983;1083-1089.
26. Parmar M.I.C.B., Freedman L.S., Hargreave T.B. et al. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on superficial bladder cancer: an analysis of 315 cases. J Urol. 142:1989;284-288.
27. Harris J.M., Sarosdy M.F. Superficial bladder tumors: the place of adjuvant intravesical chemotherapy. Abi-Aad A.S. Adjuvant treatment in urological cancer. 1997;195-211 Parthenon Publishing, London.
28. Oosterlinck W., Kurth K.H., Schroder F.H. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized tiral comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in a single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 149:1993;749-752.
29. Lamm D.L., van der Meijden A.P.M., Akaza H. Intravesical chemotherapy and immunotherapy: how do we assess their effetiveness and what are their limitations and uses? Int J Urol. 2(Suppl 2):1995;23-35.
30. Lamm D.L. BCG in perspective: advances in the treatment of superficial cancer. Eur Urol. 27(Suppl 1):1995;2-8.
31. Mulders P.F.A., Hoekstra W.J., Heybroek R.P.M. Prognosis and treatment of T1G3 bladder tumors: a prognostic factor analysis of 121 patients. Eur J Cancer. 30A:1994;914-917.
32. Pansadoro V., Emiliozzi P., Defidio L. Bacillus Calmette Guerin in the treatment of G3T1 transitional cell carcinoma of the bladder: long term results. J Urol. 154:1995;2054-2058.
33. van der Meijden APM, EORTC-GU Group members. Superficial bladder cancer-BCG current status and future trends: experience of the EORTC-GU Group, In: Abi-Aad AS, editor. Adjuvant Treatment in Urological Cancer. London: Parthenon Publishing, 1997. p. 213-227.
34. Oosterlinck W. Innovative approaches for superficial bladder tumors. Abi-Aad A.S. Adjuvant treatment in urological cancer. 1997;229-247 Parthenon Publishing, London.
35. Studer U.E., Jenzer S., Biedermann C. et al. Adjuvant treatment with a vitamin A analogue (Etretinate) after transurethral resection of superficial bladder tumors. Eur Urol. 28:1995;284-290.
36. Lamm D.L., Riggs D.R., Shriver J.S. et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 151:1994;21-26.
37. Vieweg J., Whitmore Jr W.F., Herr H.W. The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. Cancer. 74:1994;3020-3028.
38. Scher H.I. Chemotherapy for invasive bladder tumors. Prog Clin Biol Res. 353:1990;1-22.
39. Montie J.E. Follow-up after cystectomy for carcinoma of the bladder. Urol Clin North Am. 21(4):1994;639-643.
40. Herr H.W. Staging invasive bladder tumors. J Surg Oncol. 51:1992;217-220.
41. Wishnow K.I., Levinson A.K., Johnson D.E. Stage B (P2/3aN0) transitional cell carcinoma of bladder highly curable by radical cystectomy. Urol. 39:1992;12-16.
42. Freiha F.S. Invasive bladder cancer. Curr Opin Urol. 3:1993;405-408.
43. Raghavan D., Shipley W.U., Hall R.R. et al. Biology and management of invasive bladder cancer. Raghavan D., Scher H.I., Leibel S.A. et al. Principles and practice of genitourinary oncology. 1997;281-298 Lippincott-Raven, Philadelphia.
44. Lerner S.P., Skinner D.G. Radical cystectomy for bladder cancer. Vogelzang N.J., Scardino P.T., Shipley W.U. et al. Comprehensive Textbook of Genitourinary Oncology. 1996;442-463 Williams and Wilkins, Baltimore.
45. Bales G.T., Kim H., Steinberg G.D. Surgical therapy for locally advanced bladder cancer. Sem Oncol. 23(5):1996;605-613.
46. Cancrini A., De Carli P., Fattahi H. et al. Orthotopic ileal neobladder in female patients after radical cystectomy: 2 years experience. J Urol. 153:1995;956-958.
47. Hautmann R.E., Paiss T., De Petriconi R. The ileal neobladder in women: 9 years of experience with 18 patients. J Urol. 155:1996;76-81.
48. Sternberg C.N., Raghavan D., Ohi Y. Neo-adjuvant and adjuvant chemotherapy in locally advanced disease: what are the effects on survival and prognosis? Int J Urol. 2(2):1995;76-88.
49. International collaboration of trialists on behalf of the MRC Advanced Bladder Cancer Working Party, the EORTC-GU Group, the Australian Bladder Cancer Study Group, et al. Neo-adjuvant CMV chemotherapy for muscle invasive bladder cancer: results of the international trial BA06 (MRC) 30894 (EORTC), N Engl J Med 1999 (in press).
50. Crawford E.D., Natale R.B., Burton H. Southwest Oncology Group Study (8710): trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080). Prog Clin Biol Res. 353:1990;111-114.
51. Malmstrom P.U., Rintala E., Wahlqvist R. et al. Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol. 155:1996;1903-1906.
52. Wallace D.M., Raghavan D., Kelly K.A. et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 67:1991;608-615.
53. Coppin C., Gospodarowicz M., Dixon P. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or radical radiation. Proc Am Soc Clin Oncol. 11:1992;198. (Abstract 607).
54. Martinez Pineiro J.A., Gonzalez Martin M., Arocena F. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: prospective randomized phase III study. J Urol. 153:1995;964-973.
55. Pellegrini A. GISTV: Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. Eur J Cancer. 29A(Suppl 6):1993;S229. (Abstract 1284).
56. Vitale V, Orsatti M, Scarapati D. Integrated chemo-radiotherapy for infiltrating bladder cancer: an alternative approach to radical surgery, Proc Fourth Int Symp on Advances in Urol Oncol 1993;46.
57. Malmstrom P.-U., Rinalta, E., Wahlqvist R., Hellstrom P., Nilsson S., Hellsten S. and members of the Nordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic Cystectomy Trial 2. Eur Urol 1999;35(Suppl 2) abstract 238:60.
58. Splinter T.A., Scher H.I., Denis L. et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group. J Urol. 147:1992;606-608.
59. Sternberg C.N. Bladder preservation: a prospect for patients with urinary bladder cancer. Acta Oncol. 34(5):1995;589-597.
60. Herr H.W., Scher H.I. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. Cancer Treat Res. 59:1992;99-103.
61. Hall R.R., Roberts J.T., Marsh M.M. Radical TUR and chemotherapy aiming at bladder preservation. Prog Clin Biol Res. 353:1990;163-168.
62. Sternberg C.N., Pansadoro V., Lauretti S. et al. Neo-adjuvant M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy and bladder preservation for muscle infiltrating transitional cell carcinoma of the bladder. Urol Oncol. 1(3):1995;127-133.
63. Sternberg C.N., Pansadoro V. Transitional cell carcinoma of the urinary tract: bladder preserving treatments: chemotherapy and conservative surgery. Vogelzang N.J., Scardino P.T., Shipley W.U. et al. Comprehensive Textbook of Genitourinary Oncology. 1996;522-533 Williams and Wilkins, Chicago.
64. Sternberg C.N. Neo-adjuvant M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) for infiltrating transitional cell carcinoma of the urothelium. Cancer. 72:1993;1975-1982.
65. Fair W.R., Fuks Z.Y., Scher H.I. Cancer of the bladder. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practices of Oncology. 1993;1052-1072 J.B. Lippincott Co, Philadelphia.
66. Gospodarowicz M.K., Warde P. The role of radiation therapy in the management of transitional cell carcinoma of the bladder. Hematol Oncol Clin North Am. 6:1992;147-168.
67. Douglas R.M., Kaufman D.S., Zietman A.L. et al. Conservative surgery, patient selection and chemradiation as a organ-preserving treatment for muscle invading bladder cancer. Sem Oncol. 23(5):1996;614-620.
68. Oosten J.K., Janknegt R.A. Bladder saving procedure and invasive local bladder cancer. Results of 3 years follow-up in 87 responders on radiotherapy. Eur Urol. 18 Suppl:1990;79. (Abstract 159).
69. Kachnic L.A., Kaufman D.S., Heney N.M. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 15(3):1997;1022-1029.
70. Tester W., Porter A., Asbell S. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Rad Oncol Biol Phys. 25:1993;783.
71. Dunst J., Sauer R., Schrott K.M. Organ-sparing treatment of advanced bladder cancer: a 10 year experience. Int J Rad Oncol Biol Phys. 30:1994;261-266.
72. Orsatti M., Curotto A., Canobbio L. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Rad Oncol Biol Phys. 33:1995;173-178.
73. Tester W., Caplan R., Heaney J. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 14(1):1996;119-126.
74. Housset M., Dufour B., Maulard-Durdux C. et al. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol. 16(319A):1997;319A. (Abstract 139).
75. Logothetis C.J., Johnson D.E., Chong C. et al. Adjuvant cyclophosphamide, doxorubicin and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol. 6:1988;1590-1596.
76. Skinner D.G., Daniels J.R., Russell C.A. et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 145:1991;459-467.
77. Studer U.E., Bacchi M., Biedermann C. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 152:1994;81-84.
78. Stockle M., Meyenburg W., Wellek S. et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 nad pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study. J Urol. 148:1992;302-307.
79. Bono AV, Benvenuti C, Gibba A. Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study, Acta Oncol 1996.
80. Freiha F., Reese J., Torti F.M. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 155(2):1996;495-499.
81. Stockle M., Voges G.E., Meyenburg W. et al. Locally advanced bladder cancer - long term results of radical cystectomy with and without adjuvant polychemotherapy: prospective and retrospective data. J Urol. 155:1996;628A. (Abstract 1267).
82. Stockle M., Meyenburg W., Wellek S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long term results of a controlled prospective study and further clinical experience. J Urol. 153:1995;47-52.
83. Stoter G., Splinter T.A., Child J.A. et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol. 137:1987;663-667.
84. Logothetis C.J., Samuels M.L., Ogden S. et al. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. J Urol. 134:1985;460-464.
85. Loehrer P., Einhorn L.H., Elson P.J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 10:1992;1066-1073.
86. Logothetis C.J., Dexeus F., Sella A. et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors. J Clin Oncol. 8:1990;1050-1055.
87. Sternberg C.N., Yagoda A., Scher H.I. et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the bladder. J Urol. 139:1988;461-469.
88. Dimopoulos C., Finn L., Logothetis C.J. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cisplatin based chemotherapy. J Urol. 151:1994;598-601.
89. Miller R.S., Freiha F.S., Reese J.H. et al. Cisplatin, methotrexate, and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol. 150:1993;65-69.
90. Gabrilove J.L., Jakubowski A., Scher H. et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 318:1988;1414-1422.
91. Logothetis C.J., Dexeus F.H., Sella A. et al. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 82:1990;667-672.
92. Sternberg C.N. Human granulocyte colony stimulating growth factor (GM-CSF) in patients with advanced urothelial tract tumors. Marty M. Manual of GM-CSF. 1996;96-106 Blackwell Science, Oxford.
93. Sternberg C.N., de Mulder P., Fossa S. et al. Interim toxicity analysis of a randomized trial in advanced urothelial tract tumors of high-dose intensity M-VAC chemotherapy (HD-MVAC) and recombinant human granulocyte colony stimulating factor (G-CSF) versus classic M-VAC chemotherapy (EORTC 30924). Proc Am Soc Clin Oncol. 16(1140):1997;320a. (Abstract).
94. Pollera C.F., Ceribelli A., Crecco M. et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol. 5:1994;182-184.
95. Stadler W.M., Kuzel T., Roth B. et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 15(11):1997;3394-3398.
96. Lorusso V., Pollera C.F., Antimi M. et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer. 34(8):1998;1208-1212.
97. Moore M.J., Tannock I.F., Ernst D.S. et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 15(12):1997;3441-3445.
98. von der Maase H., Andersen L., Crino L. et al. A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc Am Assoc Cancer Res. 16:1997;324a. (Abstract 1155).
99. Stadler W.M., Raghavan D., Voi M. Phase II trial of gemcitabine (GEM) plus cisplatin (CDDP) in metastatic urothelial cancer. Proc Am Soc Clin Oncol. 16:1997;323a. (Abstract 1152).
100. Tu S.M., Hossa E., Amato R. et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in treatment in treatment of refractory urothelial malignancies. J Urol. 154:1995;1719-1722.
101. Vaughn D.J., Malkowicz S.B., Zoltick B.H. et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active outpatient regimen. J Urol. 157(4):1997;376. (Abstract 1471).
102. Zielinski C.C., Schnack B., Grbovic M. et al. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer. 78(3):1998;370-374.
103. Redman B.G., Smith D.C., Flaherty L. et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 16(5):1998;1844-1848.
104. Bajorin D.F., McCaffrey J.A., Hilton S. et al. Treatment of patients with transitional cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: a phase II trial. J Clin Oncol. 16(8):1998;2722-2727.
105. Roth B.J., Dreicer R., Einhorn L.H. Paclitaxel in previously untreated advanced transitional cell carcinoma of the urothelium: a phase II trial of the eastern cooperative oncology group. Proc Am Soc Clin Oncol. 13:1994;230. (Abstract 704).
106. McCaffrey J.A., Hilton S., Mazumdar M. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol. 15(5):1997;1853-1857.
107. Roth B.J., Dreicer R., Einhorn L.H. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the eastern cooperative oncology group. J Clin Oncol. 12(11):1994;2264-2270.
108. Roth B.J., Finch D.E., Birhle R. A phase II trial of ifosfamide+paclitaxel (IT) in advanced transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol. 16:1997;324a. (Abstract 1156).
109. Logothetis C., Dieringer P., Ellerhorst J. et al. A 61% response rate with 5-fluorouracil, interferon-a 2b and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma. Proc Am Assoc Cancer Res. 33:1992;221-221.
110. Kosmidis P.A., Bacoyiannis C., Fountzilas G. et al. 5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group. Ann Oncol. 8(4):1997;373-378.
111. de Mulder P., Theodore C., Sella A. et al. Phase II EORTC trial with 5-fluorouracil (5FU), cisplatin (C) and interferon-( (IFN-( 2B) as second line treatment of advanced transitional cell cancer (TCC) of the urothelial tract. Proc Am Soc Clin Oncol. 17:1998;317a. (Abstract 1221).
112. Vieweg J., Boczkowski D., Roberson K.M. Efficient gene transfer with adeno-associated virus based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 55:1995;2366-2372.
113. Saito S., Bannerij R., Gansbacher B. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54:1994;3516-3520.
114. Morris B.D., Drazan K.E., Csete M.E. Adenoviral-mediated gene transfer to bladder in vivo. J Urol. 152:1994;506-509.
115. Seigne J.D., Hu S.X., Kong C.T. et al. Rationale and development of retinoblastoma (RB) tumor suppressor gene therapy for bladder cancer. J Urol. 155:1996;320A. (Abstract).
116. Oliff A., Gibbs J.B., McCormick F. New molecular targets for cancer therapy. Sci. Am. 275(3):1996;110-115.
117. Brewster S.F., Simons J.W. Gene therapy in urological oncology: principles, strategies and potential. Eur Urol. 25:1994;177-182.
118. Hermansen D.K., Reuter V.E., WhitmoreJr W.F. et al. Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). J Urol. 140:1988;1394-1396.
119. Hug E.B., Donnelly S.M., Shipley W.U. et al. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy. J Urol. 148:1992;47-51.
120. Fojo A.T., Ueda K., Slamon D.J. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 84:1987;265-269.
121. Biedler J.L., Meyers M.B., Spengler B.A. Cellular concomitants of multidrug resistance. AnonymousMechanisms of Drug Resistance in Neoplastic Cells. Bristol Myers Symposium. 1988;Academic Press, New York.
122. Sarkis A.S., Bajorin D.F., Reuter V.E. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 13(6):1995;1384-1390.
123. Dickinson A.J., Fox S.B., Newcomb P.V. et al. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinoma. J Urol. 154:1995;237-241.
124. Liotta L., Schiffman E. Tumor autocrine motility factors. DeVita V.T., Hellman S., Rosenberg S.A. Important advances in oncology. 1988;17-30 JB Lippincott, Co, Philadelphia.
125. Fradet Y., Cordon-Cardo C., Whitmore W.F. et al. Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics. Cancer Res. 46:1986;5183-5188.
126. Bander N.H. Monoclonal antibodies in urologic oncology. Cancer. 60(Suppl 4a):1987;514-520.
127. Einstein A., Shipley W., Coombs J. et al. Randomized controlled trial of cisplatin (DDP) following preoperative radiotherapy plus radical cystectomy (RT+RCy) for invasive bladder carcinoma: a national bladder cancer collaborative group A (NBCCGA) study. Proc Am Soc Clin Oncol. 3:1984;154.